Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients

Blood

Volumn 89, Issue 5, 1997, Pages 1501-1506

  Bearman, Scott I ^a   Lee, Jung Lim ^b   Barón, Anna E ^b   McDonald, George B ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BUSULFAN; CYCLOPHOSPHAMIDE; HEPARIN; MELPHALAN; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY; TRIMETREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ARTIFICIAL VENTILATION; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIALYSIS; DRUG EFFECT; DRUG EFFICACY; FIBRINOLYTIC THERAPY; GRAFT REJECTION; HEPARINIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER VENOOCCLUSIVE DISEASE; OXYGEN THERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 1842336845     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.5.1501.1501_1501_1506     Document Type: Article

References (45)

1. Bearman SI: The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 85:3005, 1995
2. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118:255, 1993
3. Essel JH, Thompson JM, Harman GS, Halvorsen RD, Snyder MJ, Johnson RA, Rubinsak JR: Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 79:2784, 1992
4. Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R: Venocclusive disease of the liver following bone marrow transplantation. Transplantation 44:778, 1987
5. Attai M, Huguet F, Rubie H, Huynh A, Charlet J-P, Payen J-L, Voigt J-J, Brousset P, Selves J, Muller C, Pris J, Laurent G: Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 79:2834, 1992
6. Marsa-Vila L, Gorin NC, Laport JP, Labopin M, Dupuy-Montbrun MC, Fouillard L, Isnard F, Najman A: Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 47:346, 1991
7. Bearman SI, Hinds MS, Wolford JL, Petersen FB, Nugent DL, Slichter SJ, Shulman HM, McDonald GB: A pilot study of continuous infusion heparin for the prevention of hepatic venocclusive disease after bone marrow transplantation. Bone Marrow Transplant 5:407, 1990
8. Cahn JY, Flesch M, Brion A, Deconinck E, Leconte des Floris MF, Voillat L, Plouvier E, Amsallem D, Tiberghien P, Fest T, Angonin R, Carbillet JP, Herve P: Prevention of veno-occlusive disease of the liver after bone marrow transplantation: Heparin or no heparin? Blood 80:2149, 1992
9. Gluckman E, Jolivet I, Scrobohaci ML, Devergie A, Traineau R, Bourdeau-Esperou H, Lehn P, Faure P, Drouet L: Use of prosta-glandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 74:277, 1990
10. Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB: A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 84:724, 1993
11. Attal M, Huguet F, Rubie H, Charlet JP, Schlaifer D, Huynh A, Laurent G, Pris J: Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: A prospective, randomized trial. Blood 82:732, 1993
12. Essell J, Schroeder M, Thompson J, Harman G, Halvorson R, Callander N: A randomized double-blind trial of prophylactic ursodeoxycholic acid vs placebo to prevent venocclusive disease of the liver in patients undergoing allogeneic bone marrow transplantation. Blood 84:250a, 1994 (abstr, suppl 1)
13. Demuynck H, Vandenberghe P, Verhoef GEG, Zachee P, Boogaerts MA: Prevention of veno-occlusive disease of the liver after marrow and blood progenitor cell transplantation: A prospective, randomized study of different prophylactic regimens. Blood 86:620a, 1995 (abstr, suppl 1)
14. Shulman HM, Gown AM, Nugent DJ: Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Hepatol 127:549, 1987
15. Baglin TP, Harper P, Marcus RE: Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator. Bone Marrow Transplant 5:439, 1990
16. Bearman SI, Shuhart MC, Hinds MS, McDonald GB: Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 80:2458, 1992
17. Yu LC, Regueira O, Ode DL, Warner RP: Recombininant tissue plasminogen activator for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients. Am J Hematol 46:194, 1994
18. Laporte JP, Lesage S, Tilleul P, Najman A, Gorin NC: Alteplase for hepatic veno-occlusive disease complicating bone marrow transplantation. Lancet 339:1057, 1992
19. Rosti G, Bandini G, Belardinelli A, Calori E, Tura S, Gherlinzoni F, Miggiano C: Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation. Lancet 339:1481, 1992
20. Ringdén O, Wennberg L, Ericzon B-G, Kallman R, Åström M, Duraj F, Söderdahl G, Tydén G, Groth CG: Alteplase for hepatic veno-occlusive disease after bone marrow transplantation. Lancet 340:546, 1992
21. Goldberg SL, Redei I, Walsh PN, Rao AK, Klumpp TR, Mangan KF: Coagulation parameters during successful treatment of hepatic veno-occlusive disease (VOD) with low dose tissue plasminogen activator (t-PA). Blood 84:488a, 1994 (abstr, suppl 1)
22. Feldman L, Jaimovich G, Milovic V, Klein F, Gabai E, Drelichman G, Freigeiro D: Hepatic veno occlusive disease (VOD) in bone marrow transplantation (BMT). Incidence, evolution and treatment. Blood 84:708a, 1994 (abstr, suppl 1)
23. Hägglund H, Ringdén O, Ljungman P, Winiarski J, Ericzon B, Tydén G: No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation. Transplant Proc 27:3535, 1995
24. Schriber J, Christiansen N, Baer MR, Slack J, Wetzler M, Herzig G: Tissue plasminogen activator as therapy for hepatotoxicity following bone marrow transplantation. Blood 86:220a, 1995 (abstr, suppl 1)
25. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED: Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence and predisposing factors. Hepatology 4:16, 1984
26. Bearman SI, Anderson G, Mori M, Hinds MS, Shulman HM, McDonald GB: Venocclusive disease of the liver. Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 11:1729, 1993
27. Goyal RK, Wall DA, Yu LC: Identification of patients with hepatic venocclusive disease likely to respond to r-tP therapy. Blood 10:632a, 1993 (abstr, suppl 1)
28. Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R: Venocclusive disease of the liver following bone marrow transplantation. Transplantation 44:778, 1987
29. Schutt HJ, Tischler JH, Binge B, Raddatz G, Maschek H, Dietrich H, Kuse E, Pichlmayr R, Link H: Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantations-Clinical and inimunological considerations. Bone Marrow Transplant 16:473, 1995
30. Nimer SD, Milewicz AL, Champlin RE, Busuttil RW: Successful treatment of hepatic venocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation. Transplantation 49:819, 1990
31. Dowlati A, Honore P, Damas P, Deprez M, Delwaide J, Fillet G, Beguin Y: Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or-graft-versus-host disease following bone marrow transplantation. Transplantation 60:106, 1995
32. Rapoport AP, Doyle HR, Starzl T, Rowe JM, Doeblin T, DiPersio JF: Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant 8:421, 1991
33. Rhodes DF, Lee WM, Wingard JR, Pevy MD, Santos GW, Shaw BW, Wood RP, Sorrell MF, Markin RS: Orthotopic liver transplantation for graft-vs-host disease following bone marrow transplantation. Gastroenterology 99:536, 1990
34. Bunin N, Leahey A, Dunn S: Related donor liver transplant for veno-occlusive disease following T-depleted unrelated donor bone marrow transplantation. Transplantation 61:664, 1996
35. Murray JA, LaBrecque DR, Gingrich RD, Pringle KC, Mitros FA: Successful treatment of hepatic venocclusive disease in a bone marrow transplant patient with side-to-side portacaval shunt. Gastroenterology 92:1073, 1987
36. Jacobson BK, Kalayoglu M: Effective early treatment of hepatic venoocclusive disease with a central splenorenal shunt in an infant. J Pediatr Surg 27:531, 1992
37. Shulman HM, Hinterberger W: Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 10:197, 1992
38. Smith FO, Johnson MS, Scherer LR, Faught P, Breitfeld PP, Albright E, Hillier SC, Gowan D, Smith PD, Robertson KA, Emanuel D: Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant 18:643, 1996
39. Skeens J, Semba C, Dake M: Transjugular intrahepatic portosystemic shunts. Annu Rev Med 46:95, 1995
40. Palmer KJ, Goa KL: Defibrotide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 45:259, 1993
41. Bracht F, Schror K: Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun 200:933, 1994
42. Ulutin ON: Antithrombotic effect and clinical potential of defibrotide. Semin Thromb Hemost 19:186, 1993
43. Bacher P, Kindel G, Walenga JM, Fareed J: Modulation of endothelial and platelet function by a polydeoxyribonucleotide derived drug defibrotide. A dual mechanism in the control of vascular pathology. Thrombosis Res 70:343, 1993
44. Zhou Q, Chu X, Ruan C: Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 71:507, 1994
45. Richardson P, Krishnan A, Wheeler C, Ayash L, Hoppensteadt D, Fareen J, Schnipper L, Kufe D, Frei E III, Elias A: The use of defibrotide in BMT-associated veno-occlusive disease. Blood 86:221a, 1995 (abstr, suppl 1)